These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26950189)

  • 21. A family cluster of tuberculosis cases, including a case of acquired multidrug resistant tuberculosis.
    Holden J; Trachtman L
    J La State Med Soc; 2012; 164(1):43-7. PubMed ID: 22533114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic drug monitoring in tuberculosis.
    Sarkar M; Sarkar J
    Eur J Clin Pharmacol; 2024 Nov; 80(11):1659-1684. PubMed ID: 39240337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic drug monitoring in the treatment of tuberculosis patients.
    Magis-Escurra C; van den Boogaard J; Ijdema D; Boeree M; Aarnoutse R
    Pulm Pharmacol Ther; 2012 Feb; 25(1):83-6. PubMed ID: 22179055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing the clinical pharmacology of tuberculosis medications.
    Egelund EF; Alsultan A; Peloquin CA
    Clin Pharmacol Ther; 2015 Oct; 98(4):387-93. PubMed ID: 26138226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antituberculosis drugs in children.
    Schaaf HS; Garcia-Prats AJ; Donald PR
    Clin Pharmacol Ther; 2015 Sep; 98(3):252-65. PubMed ID: 26095192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis.
    de Steenwinkel JE; de Knegt GJ; ten Kate MT; van Belkum A; Verbrugh HA; Kremer K; van Soolingen D; Bakker-Woudenberg IA
    J Antimicrob Chemother; 2010 Dec; 65(12):2582-9. PubMed ID: 20947621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume.
    Vu DH; Koster RA; Alffenaar JW; Brouwers JR; Uges DR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 May; 879(15-16):1063-70. PubMed ID: 21459055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-resistant tuberculosis: resistance mechanisms and rapid susceptibility testing.
    Pfyffer GE
    Schweiz Med Wochenschr; 2000 Dec; 130(49):1909-13. PubMed ID: 11153397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prevalence of primary drug resistance in M. tuberculosis in four administrative areas of the North-Western Federal District of the Russian Federation].
    Baranov AA; Mar'iandyshev AO; Nizovtseva NI; Oparina EN; Presnova SE; Gvozdovskaia LA; Markelov IuM; Trekin IA; Tungusova OS; Mannsoker T
    Probl Tuberk Bolezn Legk; 2006; (12):9-12. PubMed ID: 17300065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges in childhood tuberculosis.
    Swaminathan S; Ramachandran G
    Clin Pharmacol Ther; 2015 Sep; 98(3):240-4. PubMed ID: 26088359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comment on: isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing.
    Köser CU; Summers DK; Archer JA
    J Antimicrob Chemother; 2011 Mar; 66(3):686-7; author reply 687. PubMed ID: 21177677
    [No Abstract]   [Full Text] [Related]  

  • 34. Compounds for use in the treatment of mycobacterial infections: a patent evaluation (WO2014049107A1).
    Pechalrieu D; Lopez M
    Expert Opin Ther Pat; 2015 Jun; 25(6):729-35. PubMed ID: 25752488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients.
    van den Elsen SHJ; Sturkenboom MGG; Akkerman OW; Manika K; Kioumis IP; van der Werf TS; Johnson JL; Peloquin C; Touw DJ; Alffenaar JC
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anti-tuberculosis drugs].
    Doi N
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():367-74. PubMed ID: 17455647
    [No Abstract]   [Full Text] [Related]  

  • 37. [Role of therapeutic drug monitoring in pulmonary infections].
    Padoin C
    Rev Mal Respir; 2017 Jun; 34(6):693-705. PubMed ID: 28528008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug resistance monitoring: combined rates may be the best indicator of programme performance.
    Van Deun A; Salim AH; Daru P; Das AP; Aung KJ; Hossain MA; Rigouts L; Fissette K; Portaels F
    Int J Tuberc Lung Dis; 2004 Jan; 8(1):23-30. PubMed ID: 14974742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Short-term chemotherapy of tuberculosis in Chile. Bacteriological considerations].
    Valenzuela P
    Rev Med Chil; 1983 Jul; 111(7):747-9. PubMed ID: 6440255
    [No Abstract]   [Full Text] [Related]  

  • 40. Limited sampling strategies for therapeutic drug monitoring of anti-tuberculosis medications: A systematic review of their feasibility and clinical utility.
    Xavier RM; Sharumathi SM; Kanniyappan Parthasarathy A; Mani D; Mohanasundaram T
    Tuberculosis (Edinb); 2023 Jul; 141():102367. PubMed ID: 37429151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.